A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia

Am J Hematol. 2022 Mar 1;97(3):E105-E109. doi: 10.1002/ajh.26444. Epub 2022 Jan 7.

Authors

Matthew S Davids¹, Mazyar Shadman^{2

3}, Sameer A Parikh⁴, Chaitra Ujjani³, Jennifer L Crombie¹, Dingfeng Jiang⁵, Cynthia Llamas⁵, Dai Feng⁵, Nicole Lamanna⁶

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
² Division of Medical Oncology, University of Washington, Seattle, Washington, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁴ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
⁵ AbbVie Inc., North Chicago, Illinois, USA.
⁶ Columbia University Medical Center, New York, New York, USA.

PMID: 34929063
DOI: 10.1002/ajh.26444

No abstract available

Publication types

Letter
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage*
Disease-Free Survival
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Male
Middle Aged
Retrospective Studies
Sulfonamides / administration & dosage*
Survival Rate

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax

Grants and funding

K12 CA087723/CA/NCI NIH HHS/United States